{
    "clinical_study": {
        "@rank": "36840", 
        "arm_group": [
            {
                "arm_group_label": "TI 30 units (10 unit + 20 unit", 
                "arm_group_type": "Experimental", 
                "description": "Technosphere\u00ae Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge"
            }, 
            {
                "arm_group_label": "TI 30 units (30 unit cartridge", 
                "arm_group_type": "Experimental", 
                "description": "Technosphere\u00ae Insulin 30 units given as one 30 unit cartridge"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 1, open-label, randomized,  crossover study in 36 healthy normal volunteers (HNVs)\n      to evaluate the bioequivalence of TI Inhalation Powder delivered using the Gen2 Inhaler and\n      administered as one 30 U cartridge versus a combination of one 10 U cartridge and one 20 U\n      cartridge."
        }, 
        "brief_title": "Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged 18 to 45 years, considered healthy based on screening physical\n             examination, medical history, clinical chemistry, and urinalysis\n\n          -  No smoking in the past 6 months (including cigarettes, cigars, and pipes)\n\n          -  Urine cotinine testing < 100 ng/mL\n\n          -  Body mass index < 32 kg/m2\n\n          -  Completion of informed consent form\n\n        Exclusion Criteria:\n\n          -  FBG > 100 mg/dL\n\n          -  Clinically significant active or chronic illness\n\n          -  History of asthma, chronic obstructive pulmonary disease (COPD), or any other\n             clinically relevant chronic lung disease\n\n          -  Respiratory tract infection within 4 weeks before screening and between the screening\n             visit and dosing visit\n\n          -  Subjects who are experiencing persistent or recurring cough, wheezing, bronchospasm,\n             or dyspnea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902121", 
            "org_study_id": "MKC-TI-178"
        }, 
        "intervention": [
            {
                "arm_group_label": "TI 30 units (10 unit + 20 unit", 
                "description": "Inhaled Insulin", 
                "intervention_name": "Technosphere\u00ae  Insulin 10U + 20U", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TI 30 units (30 unit cartridge", 
                "description": "Inhaled Insulin", 
                "intervention_name": "Technosphere\u00ae  Insulin 30U", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neptune", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07753"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-label, Randomized, Crossover Clinical Trial in Healthy Normal Volunteers to Evaluate the Bioequivalence of 30 U TI Inhalation Powder Delivered by Gen2 Inhaler Using One 30 U Cartridge Versus a Combination of 10 U and 20 U Cartridges", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area-under-the-serum insulin concentration versus time curve (AUC0-240min", 
            "safety_issue": "No", 
            "time_frame": "0, 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120,  150, 210 and 240 minutes post-TI dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902121"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mannkind Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mannkind Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}